Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Bérard P.

BMC Cancer. 2015 Nov 5;15:854. doi: 10.1186/s12885-015-1894-5.

2.

Doxycycline: new tricks for an old drug.

Barbie DA, Kennedy BK.

Oncotarget. 2015 Aug 14;6(23):19336-7. No abstract available.

3.

Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis.

Machado DE, Perini JA, Orlando MM, Santos-Oliveira R.

Biomed Res Int. 2015;2015:751460. doi: 10.1155/2015/751460. Epub 2015 Jul 9.

4.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

5.

Comparing the effectiveness and costs of Bevacizumab to Ranibizumab in patients with Diabetic Macular Edema: a randomized clinical trial (the BRDME study).

Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Van Leeuwen R, Vingerling JR, Moll AC, Schlingemann RO.

BMC Ophthalmol. 2015 Jul 7;15:71. doi: 10.1186/s12886-015-0043-x.

6.

Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.

Au JL, Lu Z, Wientjes MG.

AAPS J. 2015 Sep;17(5):1065-79. doi: 10.1208/s12248-015-9785-x. Epub 2015 Jun 19. Review.

7.

BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.

El Karak F, Assi T, Kourie HR, El Rassy E, Chebib R, Ghor M, Tabchi S.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):3294-8. eCollection 2015.

8.

Safety of octreotide in hospitalized infants.

Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB; Best Pharmaceuticals for Children Act — Pediatric Trials Network Administrative Core Committee.

Early Hum Dev. 2015 Jul;91(7):387-92. doi: 10.1016/j.earlhumdev.2015.04.008. Epub 2015 May 15.

9.

Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Morad SA, Cabot MC.

Biochim Biophys Acta. 2015 Sep;1851(9):1134-45. doi: 10.1016/j.bbalip.2015.05.001. Epub 2015 May 9. Review.

10.

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.

Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R.

Ann Oncol. 2015 Aug;26(8):1791-8. doi: 10.1093/annonc/mdv191. Epub 2015 Apr 23.

11.
12.

High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial.

Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH Jr.

PLoS One. 2015 Apr 7;10(4):e0120228. doi: 10.1371/journal.pone.0120228. eCollection 2015.

13.

Ziv-aflibercept in macular disease.

Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME.

Br J Ophthalmol. 2015 Aug;99(8):1055-9. doi: 10.1136/bjophthalmol-2014-306319. Epub 2015 Feb 12.

14.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.

J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.

15.

Endophthalmitis outbreak associated with repackaged bevacizumab.

Edison LS, Dishman HO, Tobin-D'Angelo MJ, Allen CR, Guh AY, Drenzek CL.

Emerg Infect Dis. 2015 Jan;21(1):171-3. doi: 10.3201/eid2101.141040. No abstract available.

16.

Successful long-term management of choroidal neovascularization secondary to angioid streaks in a patient with pseudoxanthoma elasticum: a case report.

Savastano MC, Minnella AM, Zinzanella G, Falsini B, Caporossi A.

J Med Case Rep. 2014 Dec 22;8:458. doi: 10.1186/1752-1947-8-458.

17.

Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis.

Grobost V, Khouatra C, Lazor R, Cordier JF, Cottin V.

Orphanet J Rare Dis. 2014 Nov 30;9:191. doi: 10.1186/s13023-014-0191-8.

18.

The off-label use of targeted therapies in sarcomas: the OUTC'S program.

Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I.

BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870.

19.

Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.

Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME.

J Clin Endocrinol Metab. 2015 Jan;100(1):E77-81. doi: 10.1210/jc.2014-2246.

20.

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G.

Cochrane Database Syst Rev. 2014 Sep 15;(9):CD011230. doi: 10.1002/14651858.CD011230.pub2. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk